In Silico Screening of Natural Compounds for Candidates 5HT6 Receptor Antagonists against Alzheimer's Disease

Molecules. 2022 Apr 19;27(9):2626. doi: 10.3390/molecules27092626.

Abstract

Alzheimer's disease (AD), a devastating neurodegenerative disease, is the focus of pharmacological research. One of the targets that attract the most attention for the potential therapy of AD is the serotonin 5HT6 receptor, which is the receptor situated exclusively in CNS on glutamatergic and GABAergic neurons. The neurochemical impact of this receptor supports the hypothesis about its role in cognitive, learning, and memory systems, which are of critical importance for AD. Natural products are a promising source of novel bioactive compounds with potential therapeutic potential as a 5HT6 receptor antagonist in the treatment of AD dementia. The ZINC-natural product database was in silico screened in order to find the candidate antagonists of 5-HT6 receptor against AD. A virtual screening protocol that includes both short-and long-range interactions between interacting molecules was employed. First, the EIIP/AQVN filter was applied for in silico screening of the ZINC database followed by 3D QSAR and molecular docking. Ten best candidate compounds were selected from the ZINC Natural Product database as potential 5HT6 Receptor antagonists and were proposed for further evaluation. The best candidate was evaluated by molecular dynamics simulations and free energy calculations.

Keywords: ADMET calculations; FEP simulations; ligand-based virtual screening; molecular docking.

MeSH terms

  • Alzheimer Disease* / drug therapy
  • Biological Products* / chemistry
  • Biological Products* / pharmacology
  • Biological Products* / therapeutic use
  • Humans
  • Molecular Docking Simulation
  • Molecular Dynamics Simulation
  • Neurodegenerative Diseases*
  • Receptors, Serotonin
  • Zinc / therapeutic use

Substances

  • Biological Products
  • Receptors, Serotonin
  • serotonin 6 receptor
  • Zinc